Use of GnRHa During Chemotherapy for Fertility Protection
Sponsor: Kenny Rodriguez-Wallberg · NCT05328258 on ClinicalTrials.gov ↗
Conditions studied
What it tests
- Triptorelin Embonatedrug
- Sodium Chloride solution 0.9%drug
Where it's running17 sites
17 international sites
- Opening soon
Center for Pediatric Cancer, Queen Silvia Hospital for Children and Youth
Gothenburg, Sweden
- Karin Mellgren(contact)
- Opening soon
Center for Pediatric Oncology, Akademiska Hospital
Gothenburg, Sweden
- Per Frisk(contact)
- Opening soon
Department of Oncology, Sahlgrenska University Hospital
Gothenburg, Sweden
- Barbro Linderholm(contact)
- Opening soon
Department of Hematology, Skåne University Hospital
Lund, Sweden
- Niklas Loman(contact)
- Opening soon
Department of Oncology, Skåne University Hospital
Lund, Sweden
- Mats Jerkerman(contact)
- Opening soon
Department of Pediatric Oncology, Skåne University Hospital
Lund, Sweden
- Helena Mörse(contact)
- Active, not recruiting
Department of Oncology, Örebro University Hospital
Örebro, Sweden
- Recruiting now
Karolinska Univeristy Hospital, Breast Centre
Stockholm, Sweden 17176
- Theo Foukakis, MD, PhD(contact)[email protected]
- Opening soon
Department of Hematology and coagulation, Sahlgrenska University Hospital
Stockholm, Sweden
- Lovisa Vennström(contact)
- Opening soon
Department of Hematology, Capio ST. Göran Hospital
Stockholm, Sweden
- Barbro Kedinge(contact)
- Opening soon
Department of Internal Medicine, Södersjukhuset
Stockholm, Sweden
- Annelie Liljegren(contact)
- Opening soon
Department of Oncology, Capio ST. Göran Hospital
Stockholm, Sweden
- Erika Isaksson Friman(contact)
- Opening soon
Department of Oncology, Södersjukhuset
Stockholm, Sweden
- Christina Linder-Stragliotto(contact)
- Recruiting now
Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet
Stockholm, Sweden
- Per Ljungman(contact)
- Recruiting now
Karolinska University Hospital, Hematology
Stockholm, Sweden
- Sara Harrysson, MD, PhD(contact)[email protected]
- Recruiting now
Karolinska University Hospital, High Specialised Pediatric Medicine
Stockholm, Sweden
- Johan Malmros, MD, PhD(contact)[email protected]
- Opening soon
Department of Oncology, Norrlands University Hospital
Umeå, Sweden
- Anne Andersson(contact)
See the official eligibility language
Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.
Inclusion Criteria: * Signed informed consent * Breast cancer or acute leukemias, lymphomas (Hodgkin and non-Hodgkin) or sarcomas (osteo, soft tissue and Ewing) confirmed by histology and assigned for diseace-specific chemotheraphy * Confirmed menarche * ECOG performance status 0-1 * Adequate bone marrow, renal, hepatic and cardiac functions and absence of other uncontrolled medical or psychiatric disorders Exclusion Criteria: * Demonstrated premature ovarian failure at time of randomization according to clinical or biochemical data * Previous or planned bilateral oophorectomy * Pregnancy or breastfeeding at time of start of chemotherapy * Other malignancy diagnosed within the last five years * Uncontrolled hypertension, heart, liver, kidney related or other uncontrolled medical or psychiatric disorders including previous or current diagnosis of anorexia * Known osteoporosis * Known low platelet count with increased bleeding risk or refractory thrombocytopenia in subjects with acute leukemias * Known or suspected allergy against triptorelin * Direct radiation of the gonads previous or planned (TBI allowed) * Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation
Updated 2023-10-27 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.